Clinical trials: Affective Disorder
Major Depressive Disorder
Stimulant Enhancement of Well-Being Therapy for Depression
This study aims to identify a novel enhancement strategy for residual symptoms of major depressive disorder (MDD) Dopamine (DA) has been viewed as a "pleasure neurotransmitter" for over 30 years.
- Trial name
- NCT01478113
- Testing
- Amphetamine/dextroamphetamine, Well-being therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Persistent Depressive Disorder
Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
The investigators aimed to assess the ability of a modified version of Behavioral Activation for occupational and social improvement to produce change in: 1. social adjustment, 2. work functioning, 3. avoidance behavior and 4.
- Trial name
- NCT01783080
- Testing
- Behavioral Activation for return to work
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
This study aims to test the effect of a newly-approved stimulant medication, lisdexamfetamine dimesylate (Vyvanse), on specific residual symptoms of depression found in some patients who are undergoing treatment with, but have…
- Trial name
- NCT01148979
- Testing
- Lisdexamfetamine Dimesylate (Vyvanse)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- NCT01473394
- Testing
- Vilazodone
- Where
- 14 sites in United States
- Volunteers
- 518 people
- Sponsor
- Forest Laboratories
Seasonal Affective Disorder
Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
The purpose of this study is to determine whether treating sleep difficulties in patients with seasonal affective disorder also improves their depressive symptoms.
- Trial name
- SAM-SAD (NCT00502320)
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Lehigh Valley Hospital
Depressive Disorder, Major
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
- Trial name
- NCT00733980
- Testing
- GSK561679
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
- Trial name
- NCT00775203
- Testing
- Trazodone Hydrochloride (HCl) Extended-Release Tablets
- Where
- 36 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Labopharm Inc.
Depression, Depressive Disorder, Major
A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise
This pilot study aims to test a model that predicts that enhanced neurotransmitter gamma-aminobutyric acid (GABA) function in reward and affect-regulation central nervous system (CNS) circuits mediates the antidepressant effects…
- Conditions
- Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression
- Trial name
- MEDEX (NCT02407704)
- Testing
- Venlafaxine XR, Aerobic Exercise, Lorazepam
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kirk Erickson, PhD
Major Depressive Disorder, Bipolar Disorder
Wake Therapy in the Treatment of Depression
This pilot study seeks to replicate previous findings that sleep deprivation results in marked improvement in depression symptoms, as well as to test whether concurrent treatment with Light Therapy and Lithium are successful in…
- Trial name
- NCT01431573
- Testing
- Wake Therapy, light box, Lithium
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Dysthymia
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression
- Trial name
- NCT03761030
- Testing
- L-DOPA
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
A Study of LY2216684 in Healthy Females
This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral contraceptive Ortho Cyclen®.
- Trial name
- NCT01373931
- Testing
- LY2216684, Ortho Cyclen
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Psychomotor Retardation, Psychomotor Slowing
Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor slowing may occur in major psychiatric disorders, such as major depressive disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills, motor planning and gross motor behavior.
- Conditions
- Psychomotor Retardation, Psychomotor Slowing, Schizophrenia and Related Disorders, Major Depressive Disorder
- Trial name
- NCT03275766
- Testing
- DLPFC facilitatory, SMA inhibitory, SMA facilitatory
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University of Bern
Major Depressive Disorder
Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression
The Researchers are going to gather information regarding the use of rTMS as a treatment for depression in adolescents with Major Depressive Disorder.
- Trial name
- NCT03363919
- Testing
- NeuroStar TMS Therapy® System, NeuroStar XPLOR®
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder, Depression, Unipolar
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
The purpose of this pilot study is to determine if taking a low dose of naltrexone in addition to an antidepressant medication can help treat relapse or recurrence in people with Major Depressive Disorder (MDD). The U.S.
- Conditions
- Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
- Trial name
- NCT01874951
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Prostate Cancer
Facilitating Participation in a Prostate Cancer Risk Assessment Program
The purpose of this study was to examine whether a cognitive-affective preparation was more beneficial, in general, and more specifically for certain subgroups, such as African-American men and individuals with high monitoring…
- Trial name
- NCT02126319
- Testing
- Cognitive Affective preparation, General Health Education
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Major Depressive Disorder (MDD)
Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression
This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
- Trial name
- NCT01683019
- Testing
- NeoSync EEG Synchronization Therapy
- Where
- 2 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Wave Neuroscience
Alcohol Use Disorder, Depressive Disorder
Intermittent Theta Burst for the Treatment of Alcohol Use Disorders in Veterans
The purpose of this study is to evaluate the efficacy of intermittent theta burst repetitive transcranial magnetic stimulation (iTBS) as a treatment for Veterans with an alcohol use disorder (AUD) to decrease the exceedingly high…
- Conditions
- Alcohol Use Disorder, Depressive Disorder, Cigarette Smoking
- Trial name
- NCT03291431
- Testing
- Intermittent theta burst transcranial magnetic stimulation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Major Depressive Disorder
Opiate Suicide Study in Patients With Major Depression
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately…
- Trial name
- AFSP (NCT04116528)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.